have been developed to treat asthma (3, (13) (14) (15) (16) (17) (18) (19) (20) . The interac-(BHR), eosinophilic inflammation, and mucus accumulation in tions between the LT, which are released early after antithe murine airways. To investigate the potential role of leukogenic provocation, and the interleukins (IL), which are protrienes (LT) in mediating these effects, we studied the ability duced and released later, are poorly understood. IL-13 is of IL-13 to induce the expression of 5-lipoxygenase (5-LO), we a major cytokine involved in allergen-induced bronchopul- 
3S*)-1-Hydroxy-3-{(3R*S*,E)-3-hydroxy-7-phenyl-1-hepten-1-yl}-Intron-differential reverse transcription-polymerase chain reaction (RT-PCR) was performed for lungs, using specific primers for 1-cyclohexane acetate, was instilled intratracheally at 1, 3, 10 or 5-LO (sequence from Genbank (NLBI, Bethesda, MD) L42198): 30 mg/kg (33, 100, 330 , and 990 g/mouse, respectively).
5Ј TACATCGAGTTCCCATGTTACCGC (282-306); 3Ј CGAT Dexamethasone (sodium salt, Sigma) was injected intravenously GCCATCCAGTAGCTCGTAAT (881-857); and ␤-actin as a conat 1.25 mg/kg (at 18 and 1 h before and 6, 24, and 48 h after trol: 5Ј ACTCCTATGTGGGTGACGAGG and 3Ј GGGAGAG challenge) (23) . Mice were killed 24 or 72 h after challenge with CATAGCCCTCGTAGAT. rmIL-13 or LT.
The cDNA were obtained as previously described (23, 30, 31) . To evaluate cell proliferation in vivo, bromodeoxyuridine (BrdU) PCR was performed at 63ЊC for annealing. Standards for ␤-actin (Sigma) was injected intraperitoneally at 120 mg/kg (27) 1 h before were prepared as previously described (31) and the specific PCR and at 50 mg/kg 1 h after the intratracheal challenge, and subseproduct for 5-LO was purified on an agarose gel. The correspondquently twice a day at 50 mg/kg until animals were killed.
ing DNA band was excised with a razor blade and then purified on a column (Ultrafree-DA (Amicon); Millipore Corp., Bedford, MA). The specificity of PCR products was verified by enzymatic diges-
Evaluation of BHR
tion. The copy number was calculated according to the optical Basal resistance of the airways and BHR were assessed in unredensity and the purified DNA was serially diluted to obtain the strained conscious animals by barometric plethysmography (Buxco appropriate standard containing 0 to 1 million copies. The copy Electronics Inc., Troy, NY). The use of the intratracheal route for number of the sample was calculated relative to the standard after delivering IL-13 or LT short-cuts the upper airways. Indeed, the PCR amplification on the LightCycler System (Roche Molecular latters' reactivity is included in the assessment with the Buxco Biochemicals, Mannheim, Germany) for 5-LO and for ␤-actin system. Bronchial reactivity was evaluated using noncumulative independently, on the same cDNA preparation. The results are methacholine challenges (23, 28, 30) . Briefly, mice were placed in given as a ratio 5-LO/␤-actin copies. a Buxco chamber and respiratory parameters were measured after MUC5AC mRNA was determined as described previously (23) . methacholine aerosol inhalation for 90 s at 60 mM (Nebulizor Type LS light; System Assistance Medical, Le Ledat, France). Resistance was calculated according to the manufacturer's recommendations
Determination of Lung Myeloperoxidase or
as: Penh (enhanced pause) ϭ (expiratory time/relaxation time) Ϫ Eosinoperoxidase Activities 1) ϫ peak expiratory flow/peak inspiratory flow. For graphic repreLungs were isolated and thoroughly washed with saline via the sentation, cumulative areas under the curve were used. pulmonary artery, then homogenized with a Potter for 1 min at 4ЊC. After centrifugation, myeloperoxidase (MPO) and eosinoperoxidase (EPO) activities were determined (23, 30) .
Bronchoalveolar Lavage Fluid
Mice were anesthetized intraperitoneally with urethane (45 mg/ Histology 30 g body wt) and the trachea was incised and cannulated. Bronchoalveolar lavage fluid (BALF) was collected with 0.5 ml followed The lungs were flushed to remove blood, then inflated with optiby 2 ϫ 1 ml of saline containing EDTA (0.005 M), phenylmethylmum cutting temperature medium (Sakura FineTek, Torrance, sulfoxide (0.005 M), dithiothreitol (0.005 M) (all from Sigma). The CA) half-diluted in saline. For paraffin inclusion, the lungs were total number of nucleated cells was determined automatically with immersed in 10% formaldehyde PBS overnight at 4ЊC and then a Coulter counter, and cytospins were prepared and colored with processed to paraffin wax. Sections 5 m in thickness were stained Diff Quick (Baxter Dade AG, Duedingen, Switzerland) for differwith periodic acid-Schiff/haematoxilin for mucins. Collagen was ential cell count.
visualized by the van Gieson acidic-picrofuschine staining technique (32) . Quantification of mucins and collagen was achieved using the Optilab Software Version 2.1 (GRASTEK, Nirmande, France)
Determination of Cys-LT and LTB4 in the BALF by
by evaluating the labeled areas and/or by counting the labeled/ ELISA, and of MUC5AC Proteins Evaluated by ELISA nonlabeled particles (for mucus). Fresh, cell-free BALF, or nitrogen-congelated cell-free BALF kept for less than 72 h were used. In some samples, a known quantity of the specific LT (LTC4 or LTB4 used as internal standards) was Immunohistochemistry added before congelation to verify the integrity of the samples Smooth muscle ␣-actin (␣-SMC) (33, 34) was determined by immuduring the time. The quantification (pg/ml) was achieved by EIA nohistochemistry. To do so, an anti-␣-SMC monoclonal antibody according to the manufacturer's instructions (Enzyme immunoasproduced in mice was applied to deparaffined lung sections folsay kit for Cys-LT or for LTB4 ; Cayman Chemicals, Ann Arbor, lowed by a biotin-conjugated antimouse antibody (Dako, Trappes, MI) as compared with a standard curve for LTB4 or Cys-LT.
France) (after neutralization of endogen peroxidase by O.3% H2O2) MUC5AC was determined by ELISA as previously deand then a streptavidin-peroxidase antibody (Dako) revealed by scribed (23) .
3-amino-9-ethylcarbazole (Sigma). Slides were counterstained by haematoxilin Gill-2 (Shandon, Pittsburg, PA). Quantification was achieved using the Optilab System. Micrographs were performed
Quantitative Reverse Transcription-Polymerase under white or polarized light, which highlightened striated structures.
Chain Reaction
Lungs were isolated and washed with saline via the pulmonary artery. Dispersion was performed with an Ultraturrax (T25 Janke
Cell Proliferation in Vivo
and Kunkel; IKA R -Labortechnik, Germany) for 30 s in the RNeasy Lysis buffer from the RNeasy Mini kit (Quiagen, Hilden, GerImmunodetection of cell-incorporated BrdU (27) was performed in the lung sections with the streptavidin-biotin system for BrdUr many) used for RNA extraction. All results are presented as means Ϯ standard deviation (n ϭ
Dexamethasone inhibited rmIL-13-induced expression 5) . Significance levels were calculated using one way analysis of of 5-LO mRNA (at 72 h, Figure 1B ) and, as a consequence, variance followed by Scheffe's test, using SPSS 6.1 software (SPSS the release of LT into the BALF ( Figure 2B ).
Inc., Chicago, IL) (significance between data at P Ͻ 0.05).
Induction of BHR by LT and Their Involvement in
Results rmIL-13-induced BHR; Drug Modulation To investigate the LT involvement in rmIL-13-induced cell
The intratracheal instillation of LTC4 or of LTB4 (1 g/d recruitment, BHR, mucus accumulation, and remodelling, for 3 d) induced BHR to methacholine 24 h after the last instillation. Under the same conditions, LTD4 and LTE4 we first studied the kinetics of LT production after the intratracheal instillation of rmIL-13, then inhibited the 5-lipoxywere more efficient ( Figure 3A ). To investigate whether LT are involved in rmIL-13-genase responsible for their synthesis or prevented the LT signal with specific receptor antagonists. In separate experiinduced BHR, zileuton was given orally at 15, 35, 50, and 70 mg/kg, twice a day. A dose-dependent inhibition of BHR ments, LT were instilled intratracheally and their effects were reduced with the corresponding receptor antagonist.
was obtained (data not shown), with a maximal inhibition chemical material contained in zileuton), injected intrave-
nously at 35 mg/kg, which is the manufacturer-recommended dose for specific 5-LO inhibition in mice, drastically reduced BHR by rmIL-13 ( Figure 3B ). The mediator role of LT was confirmed using receptor antagonists. Thus, the LTD4-ra LY 171883, instilled intratracheally 1 h before and 6 h after challenge with rmIL-13, dose-dependently inhibited BHR evaluated 24 or 72 h later ( Figure 4A ). Efficacy was obtained at 3 mg/kg (125 g/ mouse)-lower doses were inactive. The LTD4-ra MK-571 also markedly reduced BHR at 5 mg/kg (220 g/mouse) ( Figure 4B ) under the same conditions. Instilled intratracheally at 10 mg/kg (330 g/mouse), the LTB4 receptor antagonist PH-163 reduced BHR 24 and 72 h after rmIL-13 challenge ( Figure 4C) .
AT 72 h after rmIL-13, both Cys-LT-ra (LY 171,883 and MK-571) also inhibited BHR (not shown), in agreement with the elevated Cys-LT expression at that time ( Figure 2A ).
Implication of LT in rmIL-13-induced Cell Recruitment and Drug Modulation
To study the involvement of LT in cell recruitment, single instillations of LTB4, LTC4, LTD4, or LTE4 (at 1 or 2 g) were performed and failed to substantially recruit cells into Figure 5A and 5B). Both LTD4-ra inhibited BALF shown). Involvement of LT in Mucus Synthesis/Accumulation, and in Mucus Secretion after rmIL-13 rmIL-13 induces mucus accumulation in the airways (23) (24) (25) , and here we demonstrate that LT mediate this effect. Indeed, zileuton dose-dependently inhibited mucus accumulation in the lungs after rmIL-13 challenge, as shown by RT-PCR ( Figure 6A ), by ELISA for MUC5AC (Figure 6B ) and by histology ( Figure 7C , and Table 2 ). The dose providing an optimal effect was 50 mg/kg, three times a day the MUC5AC proteins measured in the BALF by ELISA, LTD4 and LTE4 being the most efficient. LTD4-induced MUC5AC protein was also reduced by the LTD4-ra ( Figure  6D ). By contrast, only a marginal mucus accumulation was tion to promoting its synthesis), LT were instilled intratracheally into mice after airways had been filled with mucus observed in the epithelial cells of the airways (Figures 7E,  7F , and 7G) after the intratracheal instillation of LT. Be-(i.e., 72 h after rmIL-13). Under these conditions, elevated levels of MUC5AC were measured in the corresponding cause ELISA revealed elevated levels of MUC5AC in the BALF, it is likely that the mucus produced is immediately BALF by ELISA ( Figure 6E ) and histology showed that epithelial cells had completely released their mucus content released into the BALF upon its production.
To assess whether they induce mucus secretion (in addi- (Figure 7Fa ). Thus, in addition to stimulating mucus synthe- sis, LT are indeed potent secretagogues. This property was Accordingly, the intense mucus-cell metaplasia observed 72 h after challenge with rmIL-13 is not or is only marginally not shared by IL-13, because only traces of MUC5AC were recovered in the BALF collected 30 min after its intratradependent on cell proliferation. Furthermore, because no proliferation of mucin-produccheal instillation under the same conditions (not shown) or 72 h after ovalbumin administration ( Figure 6E ). According cells was observed after LT instillation, it was determined that the latter are not involved in mucus cell proliferation. ingly, no acidic mucins were recovered (23) and the airways remained full of mucus, based on histology data (23) After rmIL-13 challenge, BrdU-labeled nuclei were also observed in the vascular endothelium (not shown) at the site ( Figure 7B ).
where smooth muscle cells (␣-SMA-positive) acquired a Relationship between Mucus Induction or Remodelling and fibroblast-like phenotype (proliferating and ␣-SMA-negaCell Proliferation; Role of LT tive) ( Figure 8E ). In addition, alveolar macrophages also showed marked labeling, possibly related to their morphoAt 72 h after the intratracheal instillation of 4 g of rmIL-13, only a few labeled nuclei at the basal pole of mucus-produclogic alterations observed in the BALF. The intratracheal instillation of LT failed to induce epiing cells were observed using BrdU labeling (2 Ϯ 2% in saline versus 5 Ϯ 3% after rmIL-13). After 3 instillations thelial mucin-producing cell proliferation in the bronchioles, also observed through BrdU labeling. However, LT of rmIL-13 (4 g the first day then 1 g/d for 2 d), the number of labeled nuclei increased (8 Ϯ 3%) ( Figure 8A induced a slight thickening of the endothelium of some vessels, perivascular edema, and signs of tissue disorganiza-[b]) (n ϭ 4), showing only a moderate cell proliferation. tion. In addition, LTB4 promoted fibroblast-like cell growth munocytochemistry ( Figure 8F , arrow a), was also reduced at the endothelium level ( Figure 7F ), which was prevented by zileuton ( Figure 8H , arrow a, and Table 2 ). No clear by PH-163 (not shown).
augmentation of BrdU-labeled cells was observed at this site ( Figure 8A ; data not shown), suggesting little or no cell Collagen Deposition in the Airways and in the Vessels, proliferation, but rather cell hypertrophy and remodelling. Vascular Remodelling after rmIL-13; Role of LT As early as 72 h after the intratracheal challenge, rmIL-13
Discussion
induced collagen deposition around the bronchioles, high-LT participation in human asthma, and specifically in bronlighted by van Gieson acidic picrofuschine staining (Figchial hyperreactivity, has been widely documented (2, 3, ure 8B), as well as DNA synthesis at the same site, as 5, 6, 18) . Accordingly, drugs preventing LT synthesis or evaluated by BrdU labeling (Figure 8A arrow c) . At the antagonizing their effects were developed as a treatment endothelium level, smooth muscle cells (␣-SMA-positive) and became useful tools for studying their role in animal were undergoing remodelling (with a filamentous appearance under polarized light) ( Figure 8E [a] ). Fibroblast-like models (22, 23) . Because some of the intense effects of cells appeared inside the vessels (␣-SMA negative cells, IL-13 on airways and lungs seemed to be indirect (23), we proliferating) ( Figure 8E [b] ). Striated structures observed investigated whether LT mediate its effects. We targeted with polarized light (Figure 8E ), evoking fibrills and fibers the 5-lipoxygenase responsible for LT synthesis and demonof collagen ( Figure 8D [b] ), were present around the prolifstrated the expression of its specific mRNA, the generation erating cells and obstructed the vessels ( Figure 8E , arrow of its products, and its inhibition by the 5-LO inhibitor b). Zileuton reduced these formations, as well as collagen zileuton and by specific receptor antagonists. In a second deposition in the airways and in the vessels (Figure 8C) , step, we demonstrated the direct effects of LT on BHR, reducing vascular and airways obstruction. Results after lung inflammation, mucus cell metaplasia, and remodelling. quantification with the Optilab system are summarized in
The 5-LO inhibitor zileuton was first used because it Table 2 .
inhibits the initial 5-lipoxygenase-dependent transformaDexamethasone (5 mg/kg/day) ( Figure 8G ), the LTB4-ra tion of arachidonic acid via this pathway, providing Cys-LT PH-163 (30 mg/kg, 990 g/mouse) ( Figure 8J [v] ) or zileuton (by LTC4-synthase) or LTB4 (by LTA4-hydrolase) (3, 8, (Table 2 ) reduced the local proliferation of the fibroblast-18). Two types of Cys-LT receptors have been described: like cells and collagen deposition in the airways. Edema
Cys-LT1 and Cys-LT2 (2, 18), which recognize LTD4/LTE4 observed in some perivascular zones was also suppressed and LTC4, respectively. Since LTC4 is rapidly metabolized by dexamethasone and reduced by zileuton (not shown).
in vivo by ␥-glutamyl transpeptidases into the more stable Smooth Muscle Thickening around the Airways metabolites LTD4 and LTE4 (18), LTD4-receptor antagonists were used (LY 171,883 and MK-571) (16, 17) . The The thickening of smooth muscle cells around the airways induced by rmIL-13 challenge, as observed by ␣-SMA imspecific antagonist PH-163 was used against LTB4 (19) . LT Are Expressed and Generated in the Lungs after Dexamethasone, which inhibits eosinophil and neutroProvocations with rmIL- 13 phil recruitment in the murine model (23, 35) , inhibited 5-LO expression ( Figure 1B ) and, as a consequence, LT 5-lipoxygenase mRNA were time-dependently expressed production after rmIL-13 challenges ( Figure 2B ). These in the lungs ( Figure 1A) , after intratracheal instillation of effects agree with the recognized properties of glucocorticormIL-13, as were the LT themselves (Figure 2A ). Zileuton steroids (36). selectively and reversibly inhibits 5-LO activity by complexing the iron molecule of its active site (13, 14) . Accordingly, LT Induce BHR and Mediate the Effects of rmIL-13 inhibition by zileuton of the expression of mRNA for 5-LO In humans, LT are potent bronchoconstrictor agents (5, 6) was unexpected ( Figure 1B ), suggesting either a negative and here we show the ability of each LT, particularly LTD4, regulation of the expression of the enzyme (4) or a reduced the most stable among Cys-LT, to induce BHR in mice recruitment of leukocytes after zileuton (Figure 5 ), providing less 5-LO.
( Figure 3A) . Zileuton drastically reduced BHR induced by rmIL-13, as did the LTD4 receptor antagonists, indicating scribed (3), as well as inflammatory cytokines, such as IL-13, which participate in remodelling (9, 43, 44) . that LT alone can mediate BHR induced by rmIL-13.
As early as 72 h after three instillations of LT, tissue re-LT Promote Cell Recruitment and Inflammation modeling, including edema, hypertrophy, and disorganization of the tissue were observed in association with the presThe participation of LT in the recruitment of inflammatory cells was confirmed using zileuton, which reduced the eosinence of fibroblast-like cells in the endothelium ( Figure 7F , arrow b) and with edema between airways (a) and endotheophil and neutrophil numbers in the BALF and their respective sequestration into the lungs triggered by rmIL-13 (Figlium (b) (Figure 7F, a and b, respectively) . Fibroblast proliferation was observed in vessels by rmIL-13 instillation (Figure 5) . LTB4 displayed in vivo chemotactic activity on neutrophils, which migrated into the BALF and only modure 8G), and was partially reduced by dexamethasone, and more clearly by the LTB4-receptor antagonist PH-163 (Figerately attracted eosinophils . By contrast, LTC4 attracted eosinophils and some lymphocytes (see Results). These ure 8J [v] ), and by zileuton (data not shown), suggesting LT involvement in remodelling after rmIL-13 challenge observations agree with the fact that 5-LO-deficient mice display reduced cellular response to challenge (37). (9) . Since the 5-LO expression is observed at the vascular endothelium level by in situ hybridization (45), and IL-13 Cys-LT and LTB4 Are Involved in rmIL-13-induced induces tissue fibrosis via the activation of TGF-␤1 (46), Mucus Production and Release which also produces 5-LO (46, 47), these observations sup-LT induced mucus release but little metaplasia of the airport the involvement of LT in remodelling by rmIL-13. ways epithelial cells. Nevertheless, it induces mucus synthe-
In conclusion, we have demonstrated that the pulmonary sis/production as shown by MUC5AC mRNA expression effects of IL-13, including BHR, eosinophilic inflammation, in the absence of accumulation. By contrast, rmIL-13 inneutrophilia, edema, mucus-cells metaplasia, remodelling duced a strong hyperplasia and metaplasia of mucus cells, with fibroblast proliferation, and collagen deposition inwith mucus accumulation (23) and without secretion. In volve LT, because inhibitors of their formation and Cysthis scheme, IL-13 sets the scenario for chronic mucus accu-LT1-ra or LTB4-ra were suppressive. IL-13 also promoted mulation, whereas LT promote production and immediate cell growth in the vascular endothelium, as well as tissue secretion of mucus. This might be relevant in pathologies injury and fibrosis as in humans (47); these effects were such as cystic fibrosis, because high levels of IL-13 and attenuated by dexamethasone and LT inhibitors, underlin-LTB4 have been described in the BALF of patients with ing the physiopathologic potential of LT released by IL-13. cystic fibrosis. LTB4 observed in the epithelial lining fluid Since LT promote mucus secretion in vivo, they might exert (38) might thus favor mucus secretion, and possibly airways a role in mucus clearance or promote bronchial obstruction obstruction by lack of mucus removal, because LT are also in disease, according to the specific conditions. LT are thus known to reduce mucociliary clearence. a major mediator of the in vivo effects of IL-13, in addition Multiple doses of LT are needed in vitro to induce meato their involvement in biological loops of regulation (39) . surable mucus release into the culture medium (12) . BeOur results support the increasing interest of anti-LT in cause of the limited effects of LT alone in vivo, when comtherapeutics against BHR and inflammation which might pared with their clear implication in mucus cell metaplasia be further investigated. Further studies are needed to better after rmIL-13 (as indicated by the effectiveness of zileuton understand the mechanisms responsible for mucus accumuor of the LT receptor antagonists), it is likely that LT do lation and release and those responsible for long-term pronot directly mediate mucus accumulation after rmIL-13. LT cesses such as remodelling and fibrosis. may cooperate with chemokines (39) , and (40) or cytokines
